Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Limitations
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Willeit, P.; Ridker, P.M.; Nestel, P.J.; Simes, J.; Tonkin, A.M.; Pedersen, T.R.; Schwartz, G.G.; Olsson, A.G.; Colhoun, H.M.; Kronenberg, F.; et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: Individual patient-data meta-analysis of statin outcome trials. Lancet 2018, 392, 1311–1320. [Google Scholar] [CrossRef] [Green Version]
- Kaiser, Y.; Singh, S.S.; Zheng, K.H.; Verbeek, R.; Kavousi, M.; Pinto, S.-J.; Vernooij, M.W.; Sijbrands, E.J.G.; Boekholdt, S.M.; de Rijke, Y.B.; et al. Lipoprotein(a) is robustly associated with aortic valve calcium. Heart 2021, 107, 1422–1428. [Google Scholar] [CrossRef] [PubMed]
- Kronenberg, F.; Mora, S.; Stroes, E.S.G.; Ference, B.A.; Arsenault, B.J.; Berglund, L.; Dweck, M.R.; Koschinsky, M.; Lambert, G.; Mach, F.; et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur. Heart J. 2022, 43, 3925–3946. [Google Scholar] [CrossRef] [PubMed]
- Bucci, M.; Tana, C.; Giamberardino, M.A.; Cipollone, F. Lp(a) and cardiovascular risk: Investigating the hidden side of the moon. Nutr. Metab. Cardiovasc. Dis. 2016, 26, 980–986. [Google Scholar] [CrossRef] [PubMed]
- Kamstrup, P.; Tybjærg-Hansen, A.; Nordestgaard, B. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J. Am. Coll. Cardiol. 2014, 63, 470–477. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Emdin, C.; Khera, A.; Natarajan, P.; Klarin, D.; Won, H.-H.; Peloso, G.M.; Stitziel, N.O.; Nomura, A.; Zekavat, S.M.; Bick, A.G.; et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. JACC 2016, 68, 2761–2772. [Google Scholar] [CrossRef] [PubMed]
- Dzobo, K.E.; Kraaijenhof, J.M.; Stroes, E.; Nurmohamed, N.S.; Kroon, J. Lipoprotein(a): An underestimated inflammatory mastermind. Atherosclerosis 2022, 349, 101–109. [Google Scholar] [CrossRef] [PubMed]
- Zheng, K.; Tsimikas, S.; Pawade, T.; Kroon, J.; Jenkins, W.S.; Doris, M.K.; White, A.C.; Timmers, N.K.; Hjortnaes, J.; Rogers, M.A.; et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J. Am. Coll. Cardiol. 2019, 73, 2150–2162. [Google Scholar] [CrossRef] [PubMed]
- Sianos, G.; Morel, M.A.; Kappetein, A.P.; Morice, M.-C.; Colombo, A.; Dawkins, K.; Brand, M.V.D.; Van Dyck, N.; Russell, M.E.; Mohr, F.W.; et al. The SYNTAX Score: An angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005, 1, 219–227. [Google Scholar] [PubMed]
- Dahlen, G.H. Incidence of Lp(a) lipoproteins among populations. In Lipoprotein(a); Scanu, A.M., Ed.; Academic press Inc.: Cambridge, MA, USA, 1990; pp. 151–173. [Google Scholar]
- Peter, W.; Calvin, Y.; Moriarty, P.M.; Tschiderer, L.; Varvel, S.A.; McConnell, J.P.; Tsimikas, S. Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. J. Am. Heart Assoc. 2020, 9, e016318. [Google Scholar] [CrossRef]
- Nordestgaard, B.; Langlois, M.; Langsted, A.; Chapman, M.J.; Aakre, K.M.; Baum, H.; Borén, J.; Bruckert, E.; Catapano, A.; Cobbaert, C.; et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis 2020, 294, 46–61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McNeil, M.; Buth, K.; Brydie, A.; MacLaren, A.; Baskett, R. The impact of diffuseness of coronary artery disease on the outcomes of patients undergoing primary and reoperative coronary artery bypass grafting? Eur. J. Cardio-Thoracic Surg. 2007, 31, 827–833. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ezhov, M.; Safarova, M.; Afanasieva, O.I.; Kukharchuk, V.V.; Pokrovsky, S.N. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis 2014, 235, 477–482. [Google Scholar] [CrossRef] [PubMed]
- Ezhov, M.; Afanasieva, O.; Il’Ina, L.; Safarova, M.S.; Adamova, I.Y.; Matchin, Y.G.; Konovalov, G.A.; Akchurin, R.S.; Pokrovsky, S.N. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis. Atheroscler. Suppl. 2017, 30, 187–192. [Google Scholar] [CrossRef] [PubMed]
- Pokrovsky, S.; Ezhov, M.; Il’ina, L.; Afanasieva, O.I.; Sinitsyn, V.Y.; Shiriaev, A.A.; Akchurin, R.S. Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg. 2003, 126, 1071–1075. [Google Scholar] [CrossRef] [Green Version]
- Viney, N.J.; Capelleveen, J.C.; Geary, R.S.; Xia, S.; Tami, J.A.; Yu, R.Z.; Marcovina, S.M.; Hughes, S.G.; Graham, M.J.; Crooke, R.M.; et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016, 388, 2239–2253. [Google Scholar] [CrossRef]
Type of Coronary Artery Disease | Severe Coronary Artery Calcinosis | |||||
---|---|---|---|---|---|---|
Parameters | Diffuse Lesions n = 233 | Segmental Lesions n = 157 | p | Yes n = 70 | No n = 320 | p |
Gender (female) | 51 (22%) | 36 (23%) | 0.81 | 11 (16%) | 76 (24%) | 0.18 |
Age | 64.1 ± 7.4 | 63.5 ± 8.5 | 0.65 | 63.8 ± 7.9 | 64.0 ± 7.7 | 0.88 |
Obesity | 101 (43%) | 60 (38%) | 0.35 | 30 (43%) | 131 (41%) | 0.79 |
Overweight | 98 (42%) | 78 (50%) | 0.14 | 38 (54%) | 138 (43%) | 0.09 |
Smoking | 90 (39%) | 73 (46%) | 0.14 | 28 (40%) | 135 (42%) | 0.79 |
Hypertension | 217 (93%) | 144 (92%) | 0.70 | 68 (97%) | 293 (92%) | 0.13 |
MI | 133 (57%) | 97 (62%) | 0.40 | 39 (56%) | 191 (60%) | 0.59 |
PCI | 57 (24%) | 46 (29%) | 0.29 | 16 (23%) | 87 (27%) | 0.55 |
DM | 60 (26%) | 42 (27%) | 0.91 | 22 (31%) | 80 (25%) | 0.29 |
CC | 95 (77; 114) | 96 (79; 111) | 0.62 | 95 (74; 116) | 96 (78; 112) | 0.88 |
PAD Syntax Score > 32 | 65 (28%) 181 (78%) | 42 (27%) 114 (73%) | 0.82 0.25 | 23 (33%) 54 (77%) | 84 (26%) 241 (75%) | 0.30 0.75 |
Type of Coronary Artery Disease | Coronary Artery Calcinosis | |||||
---|---|---|---|---|---|---|
Lipids | Diffuse Lesions n = 233 | Segmental Lesion n = 157 | p | Yes n = 70 | No n = 320 | p |
TC, mg/dL | 159 (135; 189) | 150 (133; 174) | 0.05 | 161 (141; 194) | 154 (133; 181) | 0.88 |
TG, mg/dL | 120 (91; 155) | 119 (91; 159) | 0.72 | 120 (97;159) | 120 (91; 156) | 0.89 |
LDL-C, mg/dL | 91 (73; 115) | 84 (70; 105) | 0.07 | 92 (75;119) | 87 (71; 109) | 0.40 |
LDL-Ccorr, mg/dL | 80 (57; 106) | 76 (55; 96) | 0.21 | 79 (63;100) | 78 (55; 102) | 0.72 |
HDL-C, mg/dL | 39 (33; 45) | 40 (34; 45) | 0.91 | 39 (32;45) | 39 (34; 45) | 0.67 |
Lp(a), mg/dL | 28 (8; 65) | 16 (6; 47) | 0.02 | 35 (11; 83) | 19 (8; 58) | 0.046 |
Risk Factors | Model 1 | p | Model 2 | p |
---|---|---|---|---|
Male gender | 1.71 (0.64–4.55) | 0.28 | 2.91 (0.91–9.33) | 0.07 |
Age | 1.03 (0.98–1.08) | 0.28 | 1.05 (0.99–1.10) | 0.11 |
Hypertension | 3.68 (0.45–30.13) | 0.22 | 4.06 (0.41–40.14) | 0.23 |
Smoking | 1.08 (0.67–1.74) | 0.75 | 0.82 (0.45–1.48) | 0.50 |
Lp(a) ≥ 30 mg/dL | 2.69 (1.30–5.57) | 0.008 | 4.29 (1.85–9.95) | 0.0007 |
LDL-Ccorr # | 1.43 (1.05–1.95) | 0.024 | 1.54 (1.07–2.24) | 0.02 |
HDL-C # | 1.28 (0.26–6.11) | 0.76 | 1.91 (0.25–14.45) | 0.52 |
Diabetes mellitus | 1.23 (0.56–2.70) | 0.60 | 1.29 (0.50–3.35) | 0.60 |
Statins | 0.33 (0.14–0.79) | 0.01 | 0.32 (0.11–0.99) | 0.05 |
Type of Coronary Artery Diseases | RR (95% CI) | p |
---|---|---|
Segmental | 1 | - |
Diffuse | 1.82 (0.58–5.68) | 0.31 |
Without calcinosis | 1 | - |
With calcinosis | 1.78 (0.58–5.49) | 0.32 |
Segmental without calcinosis | 1 | |
Diffuse without calcinosis | 1.34 (0.79–2.26) | 0.27 |
Segmental without calcinosis | 0.85 (0.06–12.21) | 0.91 |
Diffuse with calcinosis | 2.38 (1.13–5.01) | 0.02 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ilina, L.N.; Afanasieva, O.I.; Shiryaev, A.A.; Vlasova, E.E.; Kurbanov, S.K.; Afanasieva, M.I.; Ezhov, M.V.; Vasiliev, V.P.; Galyautdinov, D.M.; Pokrovsky, S.N.; et al. Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types. Biomedicines 2022, 10, 2848. https://doi.org/10.3390/biomedicines10112848
Ilina LN, Afanasieva OI, Shiryaev AA, Vlasova EE, Kurbanov SK, Afanasieva MI, Ezhov MV, Vasiliev VP, Galyautdinov DM, Pokrovsky SN, et al. Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types. Biomedicines. 2022; 10(11):2848. https://doi.org/10.3390/biomedicines10112848
Chicago/Turabian StyleIlina, Larisa N., Olga I. Afanasieva, Andrey A. Shiryaev, Elina E. Vlasova, Said K. Kurbanov, Marina I. Afanasieva, Marat V. Ezhov, Vladislav P. Vasiliev, Damir M. Galyautdinov, Sergey N. Pokrovsky, and et al. 2022. "Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types" Biomedicines 10, no. 11: 2848. https://doi.org/10.3390/biomedicines10112848
APA StyleIlina, L. N., Afanasieva, O. I., Shiryaev, A. A., Vlasova, E. E., Kurbanov, S. K., Afanasieva, M. I., Ezhov, M. V., Vasiliev, V. P., Galyautdinov, D. M., Pokrovsky, S. N., & Akchurin, R. S. (2022). Hyperlipoproteinemia(a) and Severe Coronary Artery Lesion Types. Biomedicines, 10(11), 2848. https://doi.org/10.3390/biomedicines10112848